| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.41 | 1e-14 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.26 | 1e-09 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.35 | 3e-09 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.24 | 6e-09 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.37 | 8e-08 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.3 | 3e-07 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.21 | 3e-07 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.2 | 1e-06 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.19 | 2e-06 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.25 | 8e-06 |